Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV). Co. is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. Co.'s pipeline includes: AB-729, a subcutaneously-delivered RNA interference therapeutic product candidate; AB-836, a capsid inhibitor product candidate; and other compounds early in the development process, including back-up capsid inhibitors, oral HBV RNA destabilizers and compounds that inhibit PD-L1. We show 43 historical shares outstanding datapoints in our coverage of ABUS's shares outstanding history.
Understanding the changing numbers of ABUS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABUS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABUS by allowing them to research ABUS shares outstanding history
as well as any other stock in our coverage universe. |
Free ABUS Email Alerts:
Video: Shares Outstanding Importance
